Abstract:Alcoholic hepatitis (AH) is an acute and severe form of alco1holic liver disease associated with high morbidity and mortality of 30-50% worldwide, severity ranging from asymptomatic derangement of liver biochemistries to fulminant liver failure or death. Rapidly progressing jaundice and coagulopathy in prolonged excessive alcohol abusers with or without fever, malnutrition, and tender liver are the clinical hallmarks. The prognostic models (Model for end-stage liver disease, Maddrey's discriminant function [MDF], age, serum bilirubin, INR, creatinine [ABIC], Glasgow Alcoholic Hepatitis Score [GAHS], Lille's Score) not only predict the short term mortality, but also guide the clinicians to choose appropriate specific therapy (corticosteroid or pentoxifylline) and as a stopping rule if there is no significant benefits of it. MDF Score is commonly followed in clinical practice, score of >32 would predict short term mortality of around 20-30% at 1 month and 30-40% within 6 months after presentation. The GAHS on day 1 can predict 28 day overall survival outcome accuracy of 81%, which is comparatively higher than MDF Score. Moreover, ABIC Score categorizes risk of deaths (based on 90 days) into low risks (0%), intermediate risk (30%), and high risk (75%). Corticosteroid and pentoxifylline have significant benefits in decreasing mortality (corticosteroid improves survival on 28 day and 84 day of 78% and 59%) in severe disease state (MDF >32 or Lille's Score >0.45 or GAHS >9). Corticosteroid is the initial treatment of choice with infections screening before initiating; however, pentoxifylline is better preferred in case of AH with severe infections and hepatorenal syndrome. Additionally, combination of corticosteroids and N-acetylcysteine decreases development of hepatorenal syndrome, infections, and short-term mortality. However, the Lille Score after corticosteroid therapy of >0.45 after day 7 indicates poor responders or >0.56 indicates null responders. Therefore, in these cases, either therapy has to be stopped or changed to pentoxifylline. In treatment failure cases, liver transplantation is the ultimate option. However, the facilitating of this service in most transplant centers is a challenge. Beside these specific therapies, alcohol abstinence and recommendation of nutritional supplements with high calorie, protein diet and vitamin E, C, thiamine regardless of other treatment plays a prime role in preventing disease progression and survival benefits even in pre and post-transplant cases.

Reduced Glutathione for Alcoholic Liver Disease:A Systematic Evaluation

Effect of Reduced Glutathione in Treatment of Non-alcoholic Fatty Liver Disease

Clinical Effects of Reduced Glutathione on the Treatment of Chronic Hepatitis B in Children

Effect of Reduced Glutathione Combined with Metformin in the Treatment of Non-Alcoholic Fatty Liver Disease

Effects of Reduced Glutathione and Glycyrrhizin on Treatment of Chronic Hepatitis B

Randomized controlled study on treatment of chronic hepatitis B with reduced glutathione tablet

Meta Analysis of the Curative Effect of Reduced Glutathione in the Treatment of Liver Injury Caused by Anti-tuberculosis Drugs

A Randomized Controlled Trial of Reduced Glutathione in the Treatment of Acute Renal Failure

Clinical Effects of Reduced Glutathione on the Liver Dysfunction Induced by Infection of the Bile Duct

The Clinical Studies on the Safety and Efficacy of Glutathione for Injection for Patients with Chronic Viral and Toxic Hepatitis

A multi-center clinical trial of reduced glutathione enteric-coated capsule in the management of chronic hepatitis B

Γ‐glutamylcysteine Alleviates Ethanol‐induced Hepatotoxicity Via Suppressing Oxidative Stress, Apoptosis, and Inflammation

Glutathione Deficiency-Elicited Reprogramming of Hepatic Metabolism Protects Against Alcohol-Induced Steatosis.

Reduced Glutathione for Prevention of Renal Outcomes in Patients Undergoing Selective Coronary Angiography or Intervention.

Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis

Clinical Effect of Xingnaojing Combined with Gluthion on the Serum H2O2, SOD, MDA and iNOS Levels of Patients with Acute Alcoholism

A Prognostic Evaluation and Management of Alcoholic Hepatitis

Effect of reduced glutathione on the proliferation, oxidative stress and transforming growth factor β1 expression of human hepatic stellate cells

Effect of glutathione on prognosis of liver cirrhosis patients with massive upper gastrointestinal hemorrhage

Preparation of Oxidized Glutathione and Its Therapeutic Effect on Acute Liver Injury in Mice

Effect of Reduced Glutathione on Diabetic Cardiomyopathy Patients with Heart Failure